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This brief article provides complementary data supporting the
results reported in “Changing Characteristics of Statin-related cIMT
Trials from 1988 to 2006” [1]. That article described time-related
trends in baseline factors and study characteristics that may have
inﬂuenced the variability of carotid intima media thickness (cIMT)
endpoints (mean of mean and maximum common carotid artery
[CCA]/cIMT) in published statin trials. In this brief report, additional
details for the studies included in the analysis, and further sup-
porting data, including mean of the maximum CCA/cIMT changes
and subgroup data (mean and maximum CCA/cIMT) are provided.
For the analysis, study-level data was extracted from 17 statin cIMT
trials conducted during 1988–2006, selected on the basis of having
at least one statin monotherapy arm in the absence of mixed ther-
apy, and baseline- and study-end values for mean mean and mean
maximum CCA/cIMT endpoints. The baseline mean CCA/cIMT,
maximum mean CCA/cIMT and LDL-C levels, and annualized cIMT
changes were estimated for the overall studies, those conducted
before/after 2000, and in risk-based subgroups. Interestingly, all
8 studies conducted before 2000 were signiﬁcant for cIMT change in
which patients did not receive prior LLT; whereas after 2000, the
results were more variable and in 4 of 6 trials that did not show a
signiﬁcant cIMT change, patients had received prior treatment.
Baseline mean maximum cIMT and LDL-C levels, and annualizedvier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2015.11.023
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M.H. Davidson et al. / Data in Brief 6 (2016) 530–541 531changes in studies conducted before 2000 were higher than those
conducted after 2000, similar to the results reported in the original
article for the mean mean cIMT endpoint. These ﬁndings were
consistent across study populations of patients with CHD risk versus
those without, and in studies with greater LDL-C reductions and
with thickened baseline cIMT at study entry for both mean and
maximum cIMT changes. Taken together, these results are con-
sistent with trends in recent years toward greater use of lipid-
lowering therapy and control of LDL-C that may have impacted the
variability in the results of cIMT studies.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Vascular Biology
ore speciﬁc subject area Carotid artery imaging
ype of data Tables and ﬁgures
ow data was acquired Study-level data from published statin cIMT trials
ata format Aggregate study-level data
xperimental factors Brief description of any pretreatment of samples
xperimental features Very brief experimental description
ata source location Published cIMT trials as referenced
ata accessibility Data are supplied with this articleD
Value of the data
 The relationship between baseline and study characteristics and the variability of cIMT change in
statin cIMT trials over time has not been well-studied.
 These data show time-related trends in baseline and study characteristics that may inﬂuence the
variability of mean mean and mean max cIMT results in statin clinical trials.
 Statin cIMT trials conducted before 2000 had greater cIMT baseline values, LDL-C reduction and
annualized cIMT changes than studies after 2000.
 These trends are consistent with increased statin treatment and management of LDL-C lowering
over recent years, bringing into question the utility of cIMT as a surrogate marker in clinical trials
given the high standard of background statin therapy.
 These results highlight the need to consider such factors in the design of future cIMT trials.1. Data
The predictive power of cIMT as a surrogate marker for the assessment of CVD risk reduction in
lipid-lowering trials may be limited in some settings due to differences in study design, cIMT
methods, and patient characteristics [2–4]. With increased use of lipid-lowering therapy over recent
years, it is possible that patient characteristics and study designs of cIMT trials have also changed in a
manner which could inﬂuence the utility of cIMT in assessing LLT treatment effects. This analysis was
undertaken to better understand how baseline factors and study characteristics may inﬂuence the
variability of cIMT changes in intervention trials.
A summary of the cIMT trials included in the analyses reported in the original article [1] and in this
brief report are summarized in Table 1. All 8 of the studies that were conducted before year 2000
were signiﬁcantly positive for cIMT change, and the patients in those trials did not receive prior lipid-
Table 1
Summary of the included trials.
Study
(Reference)
Treatment
(mg)nnn
Age
(yr)
Female
(%)
Population Prior treatment Study
length
(yr)
Study
(yr)
Baseline IMT thickness
(mm)
Baseline mg/dl (mmol/l)
Arm n Mean
CCA/cIMT
Mean max
CCA/cIMT
LDL-C HDL-C TG
Statin studies
ACAPSnn L20-40 231 62 49 Asymptomatic CAD; LDL-C
60–90th percentiles;
IMTZ1.5 - o3.5 mm
No prior LLT for 1 yr 3 1989–
1990
L7W¼1.15 L7W¼1.33 155 45.8
(1.19)
140
(1.58)[9] Pbo¼1.14 Pbo¼1.32 (4.01)Pbo 230
ARBITER Inn P40 70 60 29 Adults (418 yr), ATPII
lipid-lowering criteria
No prior LLT 1 1999–
2001
P¼0.615
A¼0.625
P¼0.808
A¼0.935
152 49 207
(2.34)A80 68 (3.94) (1.27)[20]
ASAPnn A80 160
163
48 61 hFH; Untreated or treated
r1 yr, LDL-C
4173 mg/dL
(4.48 mmol/l)
2 1997–
1998
A¼0.86
S¼0.87
NA 315
(8.16)
46
(1.19)
165
(1.86)[19] S40 mean CCA Z0.7 mm
and/or Z0.9 mm in bulb
BCAPSnn Met 200 61.8 54.5 Asymptomatic plaque
(focal IMT 41.2 mm) in
right coronary artery
No beta blocker or
statin
3 1991–
1994
Met¼0.92
F¼0.886
Bulb: 158
(4.09)
53.2
(1.38)
104
(1.18)[10] Met¼1.936
F¼1.893Pbo¼0.898F40 200
Pbo¼1.875Pbo 200
CAIUSnn P40 151 55 47 Moderate HC, LDL-C 150–
250 mg/dL (3.88–
6.47 mmol/l), Z1 cIMT
lesion 1.3–3.5 mm
No prior LLT r3 yr 1991–
1995
NA P¼1.06 181
(4.69)
52.5
(1.36)
138
(1.56)[15] Pbo¼1.04
Pbo 154
CAPTIVATEn Pact 100 443 55 39 hFH, LDL-C 4100 mg/dL
(42.6 mmol/l); max
cIMT40.7 -r2.5 mm
Statin Rx, 〈or〉 24 mon 1 2004–
2005
Pac¼0.785
Pbo¼0.775
Pac¼0.937
Pbo¼0.927
140
(3.63)
52
(1.35)
130
(1.47)
[16] Pbo 438
CASHMEREn A80 192 57 100 Postmenopause women
r70 yr; LDL-C 130–
190 mg/dL (3.36–
4.86 mmol/l)
No statins 43 mon w/
in last yr, or no LLT w/
in last 6 wks
1 2003–
2006
A¼0.699 NA 159
(4.12)
66.6
(1.72)
120
(1.36)
[17] Pbo 206 Pbo¼0.683
KAPSnn P40 212 57 0 LDL-C 164 mg/dL
(Z4.25 mmol/l), BMI
r32 kg/m2
No prior LLT 3 1989–
1990
1.35 (overall) NA 189
(4.90)
46
(1.19)
150
(1.70)
[18] Pbo 212
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LIPIDnn P40 273 61 12 MI or hospitalization for
unstable angina†
2 mon run-in diet, no
prior LLT
4 1990–
1992
P¼0.804
Pbo¼0.786
NA 154
(3.99)
34.7
(0.90)
151
(1.71)[13]
Pbo 249
METEORnn R40 702 61 12 Asympotmatic, moderately
elevated cholesterol with
low CVD risk per ATPIII‡
No LLT 12 mon prior 2 2002–
2004
R¼0.76 R¼1.15
Pbo¼1.17
165
(4.27)
50
(1.30)
130
(1.47)Pbo¼0.76[7]
Pbo 282
PLAC IInn P20-40a 75 61 12 CAD, LDL-C 60–90th per-
centile, Z1 IMT lesion
Z1.3 mm
No prior LLT 3 1988–
1990
P¼1.01 P¼1.32
Pbo¼1.32
166
(4.30)
41
(1.06)
171
(1.93)[6] Pbo¼1.01Pbo 76
RADIANCE
In
A10, 20,
40, 80
AþT60
454 61 12 hFH Aspirin 30%; beta
blocker 20%; ACE inh
or ARB 16–19%; E 21%
2 2003–
2004
A¼0.72
AþT¼0.71
A¼1.15
AþT¼1.09
139
(3.60)
53
(1.37)
97
(1.10)
[11] 450
RADIANCE
IIn
A10, 20,
40, 80
AþT60
375 57 37 Mixed HL eligible for statin
Rx by ATPIII; max
IMT¼1.2–3.5 mm HDL-C
r1.6 mmol/l§
Aspirin 55%, beta
blocker 24–29%; ACE
inh or ARB 37–39%; no
LLT Z4 wks
2 2003–
2006
A¼0.83
AþT¼0.83
A¼1.3
AþT¼1.32
101
(2.62)
48
(1.24)
167
(1.89)
[5] 377
REGRESSnn P40 131 56 0 CAD, symptomatic, cor-
onary angiogram Z50%
reduction in Z1 major
coronary artery¶
No LLT r6 wks
(r12 wks for ﬁbrates)
2 1989–
1991
P¼0.87
Pbo¼0.86
P¼1.08 168
(4.35)
38
(0.98)
163
(1.84)Pbo¼1.07
[8] Pbo 124
Studies with statin arms
ENHANCEn S80 342 46 51 hFH Untreated, LDL-C
4210 mg/dL
5.44 mmol/l), 81% prior
statin use
2 2002–
2006
S¼0.68
SþE¼0.68
S¼0.8
SþE¼0.8
319
(8.26)
47
(1.22)
159
(1.80)[12] S80þE10
338
VYCTORnn P40 Z18 58 57 10 yr absolute risk for CHD
or MI Z20 per ATPIII
Low dose statins, none
received E previously
1 2005 NA P¼1.33 S¼1.3
SþE¼1.23
130
(3.37)
45.3
(1.17)
192
(2.17)[14] S40
S20þE10b Z18
Z18
ARBITER IIn ERN 1000 87 67 9 Known CVD, LDL-C
o130 mg/dL
(o3.37 mmol/l) and HDL-
C o45 mg/dL
(o1.17 mmol/l)
All patients on statins
(93% S)
1 2001–
2003
ERN¼0.89
Pbo¼0.87
NA 89
(2.31)
40
(1.04)
163
(1.84)[21] Pbo 80
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A¼atorvastatin; ACE¼angiotensin-converting enzyme; ARB¼angiotensin-receptor blocker; CAD¼coronary artery disease; CHD¼coronary heart disease; CVD¼cardiovascular disease;
E¼ezetimibe; hFH¼ heterozygous familial hypercholesterolemia L¼ lovastatin; Met¼metropolo; P¼pravastatin; Pac¼pactimibe; Pbo¼placebo; S¼simvastatin; R¼rosuvastatin;
T¼torcetrapib, W¼ warfarin.
nnn Bold text denotes treatment arm in analysis.
nn Study was statistically signiﬁcant (po0.05) for primary endpoint.
n Study was non-signiﬁcant (p40.05) for primary endpoint.
† MI or hospitalization for unstable angina 3 mon–5 yr before enrollment and a total serum cholesterol 4–7 mmol/L (155–271 mg/dL) after 2 mon on low-fat diet; 88% men, 75%
infarction, 5% diabetics.
‡ LDL-C 120–190 mg/dL (3.10–4.92 mmol/l) w/0–1 CHD risk factors or 120–160 mg/dL (3.10–4.14 mmol/l) w/Z2 CHD risk factors and 10 yr risk o10%, HDL-C r60 mg/dL (1.55 mmol/l); max
IMT¼1.2–3.5 mm.
§ LDL-C r160 - 4220 mg/dL (4.1 mmol/L) w/10 yr CHD risk o10%; LDL‑C Z130 -o190mg/dL (3.37–4.92 mmol/L) w/10 yr CHD risk Z10% and r20%, LDL‑C Z115 -o190 mg/dL (2.98–
4.92 mmol/L) w/10 yr CHD risk 420%, and TG Z150 - r500 mg/dL (1.70–5.65 mmol/L).
¶ Cholesterol 155–310 mg/dl (4.01–8.03 mmol/l).
a P20 initially, change to 40 mg based on LDL-C.
b S20þE10 initially, change to S40þE based on LDL-C.
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Table 2
Pooled baseline mean maximum CCA/cIMT and annualized rates of change*.
Studies Patients Baseline mean max CCA/cIMT [mm]† Annualized change mean max CCA/cIMT [mm/yr]†‡
# N Mean (SE) Mean (SE) 95% CI
Overall 12 5051 1.0866 (0.0032) 0.0023 (0.0014) (0.0050, 0.0004)
Study year§
Before 2000 5 1955 1.2550 (0.0059) 0.0134 (0.0020) (0.0173, 0.0096)
After 2000 7 3096 1.0181 (0.0038) 0.0083 (0.0019) (0.0046, 0.0121)
CHD risk
Yes 4 1242 1.3022 (0.0071) 0.0021 (0.0030) (0.0038, 0.0081)
No 8 3809 1.0317 (0.0036) 0.0034 (0.0015) (0.0065, 0.0004)
hFH
Yes 3 1677 0.9130 (0.0050) 0.0053 (0.0024) (0.0005, 0.0100)
No 9 3374 1.2032 (0.0041) 0.0059 (0.0017) (0.0091, 0.0026)
Thickened baseline IMT¶
Yes 3 1964 1.1703 (0.0052) 0.0135 (0.0020) (0.0175, 0.0095)
No 9 3087 1.0375 (0.0040) 0.0074 (0.0019) (0.0037, 0.0111)
LDL-C reduction
o27.6% 6 3259 1.1335 (0.0042) 0.0036 (0.0016) (0.0066, 0.0005)
Z27.6% 6 1792 1.0200 (0.0050) 0.0025 (0.0030) (0.0034, 0.0083)
Mean age (yr)
o57 5 2237 0.9454 (0.0044) 0.0045 (0.0017) (0.0077, 0.0012)
Z57 7 2814 1.2423 (0.0046) 0.0023 (0.0024) (0.0024, 0.0071)
Female (%)
o40 5 1800 0.9853 (0.0058) 0.0204 (0.0043) (0.0119, 0.0289)
Z40 7 3251 1.1299 (0.0038) 0.0048 (0.0015) (0.0077, 0.0020)
hFH¼heterozygous familial hypercholesterolemia.
* Studies included: ACAPS, ARBITER I, BCAPS, CAIUS, CAPTIVATE, ENHANCE simvastatin, REGRESS, METEOR, PLAC II, VYCTOR, and RADIANCE I & II (atorvastatin arms). The PLAC II study
was excluded from the baseline analysis because of missing baseline standard error information.
† Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.
‡ SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.
§ Studies conducted before 2000: ACAPS, BCAPS, CAIUS, PLAC II, REGRESS. Studies conducted after 2000: ARBITER I, CAPTIVATE, ENHANCE, METEOR, VYCTOR, and RADIANCE I & II
(atorvastatinarms)..
¶ Entry criteria.
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M.H. Davidson et al. / Data in Brief 6 (2016) 530–541536lowering therapy. However, the 9 studies conducted after 2000 were more variable for cIMT changes
with 6 of these not showing signiﬁcant cIMT change, the majority of which (4 of 6 trials) included
patients that had received prior lipid-lowering therapy. The baseline mean mean and mean max-
imum cIMT and LDL-C levels were also generally greater for those studies conducted before 2000 than
after 2000. The durations of the trials were also longer (Z2 years) in those conducted before 2000.
Table 2 summarizes the mean maximum baseline CCA/cIMT level and annualized changes for the
overall studies (1988–2006) and those conducted before and after 2000, as well as for various study
populations. For the overall studies combined (1988–2006), the baseline mean maximum CCA/cIMT
level was 1.0866 mm and the annualized rate of change for the mean maximum CCA/cIMT from
baseline was 0.0023 mm/yr (95% CI: 0.0050, 0004), indicating a statistically signiﬁcant
annualized change in cIMT. Baseline mean maximum cIMT levels were higher in populations of
studies conducted before 2000 (1.2550 mm) than after 2000 (1.0181 mm), as well as in study
populations of patients with CHD risk versus those without, and in those studies with greater LDL-C
reductions, and those with thickened baseline cIMT. Annualized rates of change in maximum CCA/
cIMT levels were also larger for the combined study populations conducted before year 2000
(0.0134 mm/yr) than after 2000 (0.0083 mm/yr), and for those studies in which patients had
thickened baseline cIMT at study entry and also those which showed greater LDL-C reductions.
The baseline mean CCA/cIMT and annualized changes observed in pooled studies conducted before
and after 2000 for various prespeciﬁed subgroups of interest are displayed in Table 3. Consistent with
the ﬁndings in the overall analysis cohort, baseline cIMT levels and annualized change for mean CCA/
cIMT were generally greater in all subgroups assessed for the combined studies conducted before
2000 than after 2000. Similarly, mean max CCA/cIMT and annualized change in studies were also
generally greater in all subgroups assessed in studies conducted before 2000 than after 2000
(Table 4).2. Experimental design, materials and methods
2.1. Study design
This was an exploratory analysis of study-level data from statin treatment arms of published cIMT
imaging trials, as previously described in the original study article [1]. Fig. 1 displays the method of
trial selection for the analysis. Following a detailed review of cIMT trials in the literature, 24 statin
trials were identiﬁed that had both baseline- and study-end measurements for mean of the mean
CCA/cIMT (mean of all mean measurements on CCA or a single mean cIMT value when not available),
and/or mean of the maximum CCA/cIMT (mean of all maximum mean measurements on CCA, or
single maximum mean or bulb values when not available). Of these, 7 trials were excluded due to
insufﬁcient data or mixed lipid-lowering therapy in the statin arm, and 17 studies conducted during
1988–2006 were selected on the basis of having at least one statin monotherapy arm in the absence
of mixed therapy, baseline- and study-end values for mean of the mean and mean of the maximum
CCA/cIMT. The selected studies included a mix of placebo (ACAPS, ARBITER II, BCAPS, CAIUS, CAPTI-
VATE, CASHMERE, KAPS, LIPID, METEOR, PLAC II, REGRESS) and active-controlled (ARBITER I, ASAP,
RADIANCE I, RADIANCE II, ENHANCE, VYCTOR) studies (Table 1 and Fig. 1) [5–21]. There were 13 trials
with mean mean CCA/cIMT as the primary endpoint and 12 with mean maximum CCA/cIMT end-
points; these were assessed in 2 separate, but similar analyses.
2.2. Data extraction and analysis
Only aggregate data in the published literature were collected from the studies. Demographic
information (e.g., age and gender), study characteristics (study dates, CHD risk, heterozygous familial
hypercholesterolemia [FH], baseline LDL-C, HDL-C and TG levels), and baseline- and study-end
measurements for mean mean CCA/cIMT and mean max CCA/cIMT, and variability estimates were
extracted from the publications. Baseline means of the mean CCA/cIMT and maximum CCA/cIMT
levels were summarized for the overall population of studies, those conducted before and after 2000
Table 3
Pooled baseline mean mean CCA/cIMT and annualized rates of change in studies before and after 2000 for subgroups.
Studies before 2000n Studies after 2000nn
Studies Patients Baseline mean
CCA/cIMT [mm]†
Annualized change mean CCA/cIMT
[mm/yr]†‡
Studies Patients Baseline mean
CCA/cIMT [mm]
Annualized change mean CCA/cIMT
[mm/yr]†‡
# N Mean (SE) Mean (SE) 95% CI # N Mean (SE) Mean (SE) 95% CI
CHD risk
Yes 3 1201 0.8008 (0.0064) 0.0184 (0.0051) (0.0283, 0.0084) 1 375 0.8300 (0.0072) 0.0080 (0.0020) (0.0041, 0.0119)
No 2 1064 0.8898 (0.0054) 0.0098 (0.0029) (0.0155, 0.0042) 7 3131 0.7367 (0.0024) 0.0033 (0.0009) (0.0051, 0.0015)
hFH
Yes 1 281 0.8645 (0.0094) 0.0138 (0.0069) (0.0273, 0.0003) 3 1677 0.7435 (0.0036) 0.0005 (0.0012) (0.0113, 0.0057)
No 4 1984 0.8492 (0.0046) 0.0117 (0.0027) (0.0170, 0.0064) 5 1829 0.7473 (0.0029) 0.0021 (0.0012) (0.0003, 0.0043)
Thickened baseline cIMT§
Yes 1 783 0.9026 (0.0067) 0.0090 (0.0032) (0.0153, 0.0027) 4 1781 0.7782 (0.0036) 0.0085 (0.0015) (0.0113, 0.0057)
No 4 1482 0.8207 (0.0053) 0.0167 (0.0041) (0.0247, 0.0087) 4 1725 0.7242 (0.0029) 0.0023 (0.0010) (0.0003, 0.0043)
LDL-C reduction (median)
o27.6% 2 1305 0.8484 (0.0047) 0.0096 (0.0030) (0.0156, 0.0036) 4 1781 0.7782 (0.0036) 0.0021 (0.0011) (0.0000, 0.0042)
Z27.6% 3 960 0.8645 (0.0086) 0.0170 (0.0045) (0.0258, 0.0082) 4 1725 0.7242 (0.0029) 0.0066 (0.0013) (0.0092, 0.0040)
Mean age (yr)
o57 2 536 0.8645 (0.0086) 0.0148 (0.0066) (0.0277, 0.0019) 3 1677 0.7435 (0.0036) 0.0005 (0.0012) (0.0028, 0.0019)
Z57 3 1729 0.8484 (0.0047) 0.0115 (0.0027) (0.0168, 0.0061) 5 1829 0.7473 (0.0029) 0.0021 (0.0012) (0.0043, 0.0002)
Female (%)
o40 3 1201 0.8008 (0.0064) 0.0184 (0.0051) (0.0283, 0.0084) 4 1465 0.7835 (0.0040) 0.0094 (0.0019) (0.0057, 0.0130)
Z40 2 1064 0.8898 (0.0054) 0.0098 (0.0029) (0.0155, 0.0042) 4 2041 0.7277 (0.0027) 0.0040 (0.0009) (0.0058, 0.0021)
hFH¼heterozygous familial hypercholesterolemia; CHD¼coronary heart disease; IMT¼statins.
n Studies before 2000 included REGRESS, ASAP, LIPID, and BCAPS, KAPS study was excluded from the baseline analysis due to missing baseline standard error information.
nn Studies after 2000 included ARBITER I, METEOR, CASHMERE, CAPTIVATE, ENHANCE (simvastatin arm), ARBITER II (placebo arm), and Radiance I & II (atorvastatin arm).
† Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.
‡ SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.
§ Entry criteria.
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Table 4
Pooled baseline mean maximum CCA/cIMT and annualized rates of change in studies before and after 2000* for subgroups.
Studies before 2000* Studies after 2000nn
Studies Patients Baseline max CCA/
cIMT [mm]†
Annualized change max CCA/cIMT
[mm/yr]†‡
Studies Patients Baseline max CCA/
cIMT [mm]
Annualized change max CCA/cIMT
[mm/yr]†‡
# N Mean (SE) Mean (SE) 95% CI # N Mean (SE) Mean (SE) 95% CI
CHD risk
Yes 3 867 1.3028 (0.0080) 0.0140 (0.0038) (0.0215, 0.0066) 1 375 1.3000 (0.0150) 0.0300 (0.0050) (0.0202, 0.0398)
No 2 1088 1.1975 (0.0088) 0.0132 (0.0023) (0.0177, 0.0087) 6 2721 0.9989 (0.0039) 0.0046 (0.0021) (0.0005, 0.0087)
hFH
Yes 0 0 – – – 3 1677 0.9130 (0.0050) 0.0053 (0.0024) (0.0005, 0.0100)
No 5 1955 1.2550 (0.0059) 0.0134 (0.0020) (0.0173, 0.0096) 4 1419 1.1547 (0.0057) 0.0135 (0.0032) (0.0074, 0.0197)
Thickened baseline cIMT§
Yes 2 1088 1.1975 (0.0088) 0.0132 (0.0023) (0.0177, 0.0087) 1 876 1.1553 (0.0065) 0.0145 (0.0042) (0.0228, 0.0062)
No 3 867 1.3028 (0.0080) 0.0140 (0.0038) (0.0215, 0.0066) 6 2220 0.9486 (0.0046) 0.0143 (0.0022) (0.0101, 0.0186)
LDL-C reduction (median)
o27.6% 3 1549 1.2642 (0.0061) 0.0136 (0.0020) (0.0176, 0.0097) 3 1710 1.0180 (0.0057) 0.0112 (0.0024) (0.0064, 0.0160)
Z27.6% 2 406 1.0747 (0.0269) 0.0088 (0.0095) (0.0275, 0.0099) 4 1386 1.0181 (0.0050) 0.0037 (0.0031) (0.0025, 0.0098)
Mean age (yr)
o57 2 560 1.0515 (0.0091) 0.0132 (0.0023) (0.0177, 0.0087) 3 1677 0.9130 (0.0050) 0.0053 (0.0024) (0.0005, 0.0100)
Z57 3 1395 1.4045 (0.0078) 0.0139 (0.0038) (0.0214, 0.0065) 4 1419 1.1547 (0.0057) 0.0135 (0.0031) (0.0074, 0.0197)
Female (%)
o40 2 406 1.0747 (0.0269) 0.0088 (0.0095) (0.0275, 0.0099) 3 1394 0.9809 (0.0060) 0.0280 (0.0049) (0.0185, 0.0375)
Z40 3 1549 1.2642 (0.0061) 0.0136 (0.0020) (0.0176, 0.0097) 4 1702 1.0430 (0.0049) 0.0047 (0.0021) (0.0006, 0.0088)
hFH¼heterozygous familial hypercholesterolemia; CHD¼coronary heart disease; cIMT¼carotid intima media thickness.
* Studies conducted before 2000: ACAPS, BCAPS, CAIUS, PLAC II, REGRESS.
** Studies conducted after 2000: ARBITER I, CAPTIVATE, ENHANCE, METEOR, VYCTOR, and RADIANCE I & II (atorvastatin arms).
† Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.
‡ SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.
§ Entry criteria.
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Fig. 1. Study selection ﬂow chart.
M.H. Davidson et al. / Data in Brief 6 (2016) 530–541 539(the median of enrollment dates for all studies), and studies that enrolled patients based on CHD risk,
heterozygous FH, and thickened baseline cIMT. Subgroups of patients categorized by LDL-C reduction,
age and gender were also assessed. Dichotomized variables for the subgroups were prespeciﬁed
based on median values for the combined studies.
Studies were combined using a meta-analytic approach. The 13 trials included in the mean mean
CCA/cIMT analysis were: ARBITER I, REGRESS, ASAP, KAPS, LIPID, METEOR, BCAPS, CASHMERE, CAP-
TIVATE, ENHANCE (simvastatin), ARBITER II (placebo), and Radiance I & II (atorvastatin). The 12
studies included in the analysis of mean maximum CCA/cIMT were: ACAPS, ARBITER I, BCAPS, CAIUS,
CAPTIVATE, ENHANCE (simvastatin), REGRESS, METEOR, PLAC II, VYCTOR, and RADIANCE I & II
(atorvastatin).
Study-end values were reported as a change from baseline in primary variables (mean mean or
mean max CCA/cIMT) indicating regression and/or progression of cIMT. Annualized rates of change
(regression and/or progression) were extracted as treatment differences for placebo-controlled stu-
dies and as change from baseline in each individual treatment arm for active-control studies. For
active-controlled studies with 2 or more monotherapy arms, each treatment arm was included in the
analysis as a separate data point. For trials in which annualized rates of change was not provided, it
was calculated by dividing the reported change in cIMT by the duration of the study in years.
Estimates of variance for the baseline and study-end values for mean mean and mean max cIMT
were extracted from the publications. In most cases the standard deviation was reported for baseline
values and the standard error (SE) was reported for study-end values. In some instances the SE was
not reported, and it was calculated from the reported 95% CIs or p-values for the treatment difference
(placebo-controlled) or change from baseline (monotherapy arms) in cIMT. The rate of cIMT change
was standardized (annualized) for this analysis; however, the SE reported in the publication was used
regardless of study duration. An overall pooled estimate for the baseline CCA/ cIMT value and
annualized rate of cIMT change was calculated by weighting each individual study by the inverse of
the square of its standard error which was extracted from the publications. This resulted in studies
with small variability having more weight in the pooled values than studies with large variability.
Overall pooled estimates for the baseline CCA/cIMT value and annualized rate of change for mean of
mean CCA and mean of max cIMT, were calculated using a ﬁxed-effects model, by weighting each
individual study by the inverse of the square of its standard error; thus, studies with small variability
had more weight in the pooled values than studies with large variability.Source of funding
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